PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18774637-5	2008	Lapatinib inhibited the phosphorylation of HER2, EGFR and downstream signaling proteins, resulting in G1 arrest in both cell lines with down-regulation of cMyc and induction of p27kip1.	Lapatinib	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	155-159	
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	0-9	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104	
26461093-4	2015	Lapatinib-induced FOXO transcription factors, normally tumor-suppressing, paradoxically upregulate c-Myc epigenetically in concert with a cascade of MLL2-associating epigenetic regulators to dampen sensitivity of the cancer cells to lapatinib.	Lapatinib	233-242	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	99-104	
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	36-41	
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	133-138	
26461093-5	2015	An epigenetic inhibitor suppressing c-Myc synergizes with lapatinib to suppress cancer growth in vivo, partly by repressing the FOXO/c-Myc axis, unraveling an epigenetically regulated FOXO/c-Myc axis as a potential target to improve therapy.	Lapatinib	58-67	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	133-138	
27416292-8	2016	Specially, lapatinib activated both the c-Myc/pro-Nrf2 pathway and GSK-3beta signaling to stabilize Nrf2 and maintain a low level of ROS in resistant cells.	Lapatinib	11-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	40-45	
27416292-9	2016	However, berberine can upset the ROS balance by downregulating c-Myc to reverse the lapatinib resistance.	Lapatinib	84-93	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	63-68	
28744398-9	2017	Furthermore, the Lapatinib induced increased ERK phosphorylation is correlated with increased stability of c-Myc, which is known to be stabilized by ERK-mediated phosphorylation.	Lapatinib	17-26	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	107-112	
30123134-12	2018	In validating experiments, combination of Lapatinib and all-trans retinoic acid (ATRA) synergistically suppresses cell growth, and accompanied by decreased expression of MYC.	Lapatinib	42-51	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	170-173	
29169418-10	2017	Conclusion Lapatinib could inhibit cell proliferation and promote apoptosis in HL60 cells by inhibiting the CIP2A/AKT/c-MYC signal pathway.	Lapatinib	11-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	118-123	
27157613-6	2016	TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16.	Lapatinib	7-16	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	150-155